

Rafael Dal-R Tenreiro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2864413/rafael-dal-re-tenreiro-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82

papers

524

citations

11

h-index

20

g-index

102

ext. papers

777

ext. citations

5.3

avg, IF

5.32

L-index

#	Paper	IF	Citations
82	Single research ethics committee review for multinational trials is a misconception.. <i>Journal of the Royal Society of Medicine</i> , 2022 , 1410768211066909	2.3	1
81	It is time to include real-world effectiveness data on medicinal product labels.. <i>Lancet Respiratory Medicine</i> , 2022 ,	35.1	0
80	August 2021 and the Delta variant: is mandatory vaccination of individuals against SARS-CoV-2 acceptable?. <i>Medicina Clínica (English Edition)</i> , 2022 , 158, 233-233	0.3	
79	Ethical concern regarding the UK PANORAMIC COVID-19 trial.. <i>British Journal of Clinical Pharmacology</i> , 2022 ,	3.8	1
78	High heterogeneity on the accepted vaccines for COVID-19 certificates in European countries.. <i>Travel Medicine and Infectious Disease</i> , 2022 , 102321	8.4	0
77	European non-commercial sponsors showed substantial variation in results reporting to the EU trial registry. <i>Journal of Clinical Epidemiology</i> , 2021 , 142, 161-170	5.7	2
76	Placebo control group in COVID-19 vaccine trials: context and timing matters. <i>European Journal of Clinical Pharmacology</i> , 2021 , 78, 523	2.8	
75	For how long and with what relevance do genetics articles retracted due to research misconduct remain active in the scientific literature. <i>Accountability in Research</i> , 2021 , 28, 280-296	1.9	5
74	Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 2405-2406	3.8	2
73	Thoughtful selection and use of scientific terms in clinical research: the case of pragmatic trials. <i>Journal of Investigative Medicine</i> , 2021 , 69, 1056-1058	2.9	1
72	Trial participants' rights after authorisation of COVID-19 vaccines. <i>Lancet Respiratory Medicine</i> , 2021 , 9, e30-e31	35.1	10
71	Being fair to participants in placebo-controlled COVID-19 vaccine trials. <i>Nature Medicine</i> , 2021 , 27, 938	50.5	1
70	Clinical Equipoise in COVID-19 Vaccine Candidate Trials. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 1249-1250	12.5	2
69	When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine. <i>European Journal of Internal Medicine</i> , 2021 , 87, 1-2	3.9	1
68	"Let me choose my COVID-19 vaccine". <i>European Journal of Internal Medicine</i> , 2021 , 87, 104-105	3.9	9
67	Mandatory Coronavirus Disease 2019 Vaccine for Children?. <i>JAMA Pediatrics</i> , 2021 , 175, 533-534	8.3	0
66	Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. <i>Lancet Infectious Diseases</i> , 2021 , 21, e342-e347	25.5	10

65	Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label. <i>Vaccine</i> , 2021 , 39, 4029-4031	4.1	4
64	Placebo-controlled trials with COVID-19 vaccines: participants first. <i>Journal of Clinical Epidemiology</i> , 2021 , 138, 211-212	5.7	2
63	Acceso a los resultados de los ensayos clínicos no comerciales con medicamentos realizados en España. <i>Revista Clinica Espanola</i> , 2021 , 222, 116-116	0.7	
62	The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 539-546	2.8	3
61	Pragmatic trials, blinding, placebos, and the usefulness of the PRECIS-2 tool. <i>European Journal of Clinical Pharmacology</i> , 2021 , 77, 1071-1072	2.8	
60	US FDA erratic approach to placebo-controlled trials after issuing an emergency use authorization for a COVID-19 vaccine. <i>Vaccine</i> , 2021 , 39, 1180-1182	4.1	2
59	Remdesivir for COVID-19 in Europe: will it provide value for money?. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 127-128	35.1	8
58	Who should be vaccinated against COVID-19 first?. <i>Medicina Clínica (English Edition)</i> , 2021 , 156, 177-179	0.3	2
57	Current COVID-19 vaccine trials in high-income countries: are placebo-controlled trials ethical?. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1565-1567	9.5	3
56	Access to the results of non-commercial clinical trials with medicines conducted in Spain. <i>Revista Clínica Espanola</i> , 2021 , 222, 116-116	0.5	
55	Participant-funded clinical trials on rare diseases. <i>Anales De Pediatrã (English Edition)</i> , 2020 , 93, 267.e1-267.e9	0	0
54	Articles provided insufficient information to conduct an appropriate retrospective assessment of the pragmatic/explanatory features of medicine trials with the PRECIS-2 tool. <i>European Journal of Clinical Pharmacology</i> , 2020 , 76, 1093-1102	2.8	7
53	Leveraging Data Science for a Personalized Haemodialysis. <i>Kidney Diseases (Basel, Switzerland)</i> , 2020 , 6, 385-394	3.3	3
52	The need to implement non-industry COVID-19 clinical trials in non-high-income countries. <i>Journal of Global Health</i> , 2020 , 10, 010351	4.3	
51	Participants' written informed consent in low-risk pragmatic clinical trials with medicines. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 205-210	3.8	
50	Unperceived similarities between clinical trials and quantum physics. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 192-193	3.8	1
49	Should research misconduct be criminalized?. <i>Research Ethics</i> , 2020 , 16, 1-12	2.8	24
48	Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 1903-1904	27.4	6

47	Analysis of biomedical Spanish articles retracted between 1970 and 2018. <i>Medicina Clínica</i> , 2020 , 154, 125-130	1	1
46	Clinical trials: generalizability is much more than representativeness. <i>European Journal of Internal Medicine</i> , 2020 , 79, 123	3.9	2
45	The design can limit PRECIS-2 retrospective assessment of the clinical trial explanatory/pragmatic features. <i>Journal of Clinical Epidemiology</i> , 2020 , 126, 193-201	5.7	6
44	Reporting the details of consent procedures in clinical trials. <i>Journal of Clinical Epidemiology</i> , 2020 , 117, 150-151	5.7	1
43	On the semantics of clinical trials. The case of a pragmatic trial in Alzheimer's disease. <i>European Journal of Neurology</i> , 2020 , 27, e14	6	1
42	Waste in COVID-19 clinical trials conducted in western Europe. <i>European Journal of Internal Medicine</i> , 2020 , 81, 91-93	3.9	7
41	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. <i>BMJ Evidence-Based Medicine</i> , 2020 ,	2.7	8
40	Changes in ongoing clinical trial protocol designs behind the scenes. <i>European Journal of Internal Medicine</i> , 2020 , 78, 32-33	3.9	
39	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 1067-1072	3.8	0
38	COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 445-447	3.1	1
37	Mandatory disclosure of financial interests of journals and editors. <i>BMJ, The</i> , 2020 , 370, m2872	5.9	2
36	Low risk pragmatic trials do not always require participants' informed consent. <i>BMJ, The</i> , 2019 , 364, l10929	3.9	17
35	Plan S: Funders are committed to open access to scientific publication. <i>European Journal of Clinical Investigation</i> , 2019 , 49, e13100	4.6	3
34	A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. <i>Journal of Clinical Epidemiology</i> , 2019 , 114, 60-71	5.7	5
33	Analysis of retracted articles on medicines administered to humans. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2179-2181	3.8	2
32	Who are the Spanish sponsors of the higher number of non-commercial clinical trials with medicines and of the reporting of their results?. <i>Medicina Clínica (English Edition)</i> , 2019 , 153, e3-e4	0.3	
31	Editors' and authors' individual conflicts of interest disclosure and journal transparency. A cross-sectional study of high-impact medical specialty journals. <i>BMJ Open</i> , 2019 , 9, e029796	3	11
30	Reasons for and time to retraction of genetics articles published between 1970 and 2018. <i>Journal of Medical Genetics</i> , 2019 , 56, 734-740	5.8	11

29	Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clínica (English Edition)</i> , 2019 , 152, 78-79	0.3	
28	Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines. <i>Medicina Clínica</i> , 2019 , 152, 78-79	1	
27	Who are the Spanish sponsors of the higher number of non-commercial clinical trials with medicines and of the reporting of their results?. <i>Medicina Clínica</i> , 2019 , 153, e3-e4	1	2
26	Potential predatory journals are colonizing the ICMJE recommendations list of followers. <i>Netherlands Journal of Medicine</i> , 2019 , 77, 92-96	0.5	4
25	Are article's social media mentions associated to citation counts? An analysis in highly influential medical journals. <i>Revista Clínica Española</i> , 2018 , 218, 40-42	0.5	1
24	2017, a key year on clinical trials transparency. <i>Medicina Clínica (English Edition)</i> , 2018 , 150, 80-81	0.3	
23	Clinical Trials Transparency: Where Are We Today?. <i>Trends in Cancer</i> , 2018 , 4, 1-3	12.5	0
22	What most influent psychiatry journals do not show. <i>Revista De Psiquiatría Y Salud Mental</i> , 2018 , 11, 256-257		1
21	Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic?. <i>BMC Medicine</i> , 2018 , 16, 49	11.4	92
20	Preregistration and publication of nonregulated intervention trials are here to stay (letter commenting Wallach et al 2018, 93, 88-93). <i>Journal of Clinical Epidemiology</i> , 2018 , 99, 167-168	5.7	2
19	Are article's social media mentions associated to citation counts? An analysis in highly influential medical journals. <i>Revista Clínica Española</i> , 2018 , 218, 40-42	0.7	3
18	2017, a key year on clinical trials transparency. <i>Medicina Clínica</i> , 2018 , 150, 80-81	1	0
17	Are journals following the ICMJE recommendations complying with conflicts of interest disclosure policies. <i>European Journal of Internal Medicine</i> , 2018 , 57, e17-e19	3.9	4
16	Assessment of Pragmatism in Recently Published Randomized Clinical Trials. <i>JAMA Internal Medicine</i> , 2018 , 178, 1278-1280	11.5	20
15	Efficacy and effectiveness: The wrong use of different terms. <i>European Journal of Internal Medicine</i> , 2018 , 54, e17-e18	3.9	5
14	Journals' TOP guidelines transparency level should be disclosed. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 249-250	2.8	
13	Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial. <i>Journal of Evaluation in Clinical Practice</i> , 2018 , 24, 258-261	2.5	9
12	How to improve the integrity of clinical trial articles. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2018 , 11, 189-191	0.2	

11	Adherence to the International Committee of Medical Journal Editors (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals. <i>Trials</i> , 2018 , 19, 448	2.8	31
10	Financial conflicts of interest in medical journals. <i>Emergencias</i> , 2018 , 30, 201-204	0.9	
9	Outcome reporting bias in clinical trials: why monitoring matters. <i>BMJ, The</i> , 2017 , 356, j408	5.9	38
8	Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1921-1931	3.8	8
7	Do opinion articles attract more social attention than original research, relative to their citation counts?. <i>European Journal of Internal Medicine</i> , 2017 , 42, e27-e30	3.9	4
6	Who is willing to participate in low-risk pragmatic clinical trials without consent?. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 1557-1563	2.8	2
5	Comparative effectiveness medicines research cannot assess efficacy. <i>Journal of Clinical Epidemiology</i> , 2017 , 92, 129	5.7	1
4	International trials in middle-income countries: different local scenarios require different ethical approaches. <i>Journal of the Royal Society of Medicine</i> , 2016 , 109, 47-51	2.3	2
3	Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. <i>Journal of Clinical Epidemiology</i> , 2016 , 75, 100-7	5.7	39
2	Prevention of selective outcome reporting: let us start from the beginning. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1283-1288	2.8	18
1	When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process. <i>Clinical Pharmacology and Therapeutics</i> , 2008 , 83, 788-93	6.1	13